- Home
- EQV vs ORGO Comparison
EQV vs ORGO Comparison
Compare EQV & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQV
- ORGO
- Stock Information
- Founded
- EQV 2024
- ORGO 1985
- Country
- EQV United States
- ORGO United States
- Employees
- EQV N/A
- ORGO N/A
- Industry
- EQV
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- EQV
- ORGO Health Care
- Exchange
- EQV Nasdaq
- ORGO Nasdaq
- Market Cap
- EQV 472.5M
- ORGO 384.4M
- IPO Year
- EQV 2024
- ORGO N/A
- Fundamental
- Price
- EQV $10.62
- ORGO $3.25
- Analyst Decision
- EQV
- ORGO Buy
- Analyst Count
- EQV 0
- ORGO 2
- Target Price
- EQV N/A
- ORGO $5.50
- AVG Volume (30 Days)
- EQV 209.9K
- ORGO 911.8K
- Earning Date
- EQV 01-01-0001
- ORGO 08-07-2025
- Dividend Yield
- EQV N/A
- ORGO N/A
- EPS Growth
- EQV N/A
- ORGO N/A
- EPS
- EQV N/A
- ORGO N/A
- Revenue
- EQV N/A
- ORGO $458,760,000.00
- Revenue This Year
- EQV N/A
- ORGO $2.62
- Revenue Next Year
- EQV N/A
- ORGO $12.46
- P/E Ratio
- EQV $51.68
- ORGO N/A
- Revenue Growth
- EQV N/A
- ORGO 5.35
- 52 Week Low
- EQV $9.88
- ORGO $2.28
- 52 Week High
- EQV $10.74
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- EQV N/A
- ORGO 48.02
- Support Level
- EQV N/A
- ORGO $3.08
- Resistance Level
- EQV N/A
- ORGO $3.71
- Average True Range (ATR)
- EQV 0.00
- ORGO 0.21
- MACD
- EQV 0.00
- ORGO 0.07
- Stochastic Oscillator
- EQV 0.00
- ORGO 55.45
About EQV EQV Ventures Acquisition Corp.
EQV Ventures Acquisition Corp is a blank check company.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.